Glanbia Performance Nutrition (GPN) has enjoyed increased revenue so far this year thanks to its €300 million SlimFast acquisition but importing difficulties led to a 'disappointing' like-for-like volume performance, the firm's nine-month...
Blackmores' in-market sales in China dipped in the first half of the financial year, causing its shares to slide and emphasising the difficulty in shifting from a daigou-based model to domestic Chinese trade.
Glanbia, the Kilkenny headquartered global nutrition and dairy products group reported an eighth year of double-digit growth in today’s 2017 full year earnings announcement.
Swiss-based biotech Evolva is looking to triple is sales in 2017 as the firm takes steps to transform from a research focus into a product-based company.
Vitamin Shoppe reported comparable store sales declines and a big drop in its contract manufacturing arm as the company continues to work on controlling costs and launching a new store concept.
Company to sell 60% stake in Dairy Ireland to Irish co-op
Glanbia reported better than expected growth in 2016 with performance nutrition driving revenue and profits, said the firm as it announced the part sell-off of its Irish dairy business.
In US basketball lingo they call it playing small ball. Frutarom, which supplies flavors, fragrances and dietary supplement ingredients, has grown to one of the world’s largest companies in the category by acquiring many of the smallest firms.
UK nutrition firm Sciences in Sport made a €1.4m first-half loss before tax as a result of heavy marketing investment, but saw revenues rise 19% to €7.1m, the company announced.
Kerry Foods has suffered losses as a result of heavy promotional activity caused by the major multiples in response to the growth of the German discounters Aldi and Lidl.
Stepan Co. had high hopes when it acquired a brace of branded lipid nutritional ingredients - Clarinol and Marinol - in 2011. But the company growth projections have been frustrated as several factors have conspired to drive down demand and revenues in...
Strong growth in health and nutrition, coupled with increasing demand for cultures and enzymes in Europe and the Americas has led Chr. Hansen to a ‘solid’ performance in Q1, says the firm.
French botanicals giant Naturex said first half results had been dented by a difficult macroeconomic environment and exchange rates, despite restructuring and acquisition moves.
Danish ingredients company Chr. Hansen has reported increased profit and revenue in the first quarter, although lower carmine prices and volumes continued to hit its natural colours division.
BASF’s nutrition and health unit (N&H) earned €492m in Q3 – 4% more for the quarter than in 2011 when it had sales of €471m – despite falling prices for most vitamins.
Krill specialist Aker BioMarine is looking at expanding production after its Q2 results showed operating revenue growth of 23% from NOK87m (€11.91m) in Q2 2011, to NOK107m (€14.65m) in Q2 2012.
DuPont posted higher profits and revenue for the first quarter of 2012, citing higher prices and increased sales in developing markets, as well as continuing benefit from last year’s acquisition of Danish specialty ingredients firm Danisco.
DuPont benefited from last year’s acquisition of Danish specialty food ingredient company Danisco in the fourth quarter of 2011, as revenue more than doubled in its nutrition and health business – although the chemical group’s overall profit fell slightly.
Canadian krill oil firm Neptune Technologies & Bioressources has posted a 20% rise in third-quarter revenues to $5.12m in its nutraceuticals business and a $869,000 net profit compared with a $13,000 loss for the same period the previous year.
Dupont, which earlier in the year warned that its May $6.49bn acquisition of Danisco would dent its yearly profits, has defied expectations in second quarter results published today.
French botanicals supplier Naturex has seen its 2011 Q1 net profit double from €2.4m to €4.8m on revenues of €64m, as benefits of its 2009 expansion kick in.
Chinese supplements maker Tiens Biotech Group (USA) has seen revenues increase from $11.4m in Q1 2010 to $13.1m in the first quarter of 2011, as it consolidates its Chinese and international business.
Danish bioscience firm Chr. Hansen is raising its revenue predictions by 11-13 per cent for 2010/11 after what it describes as “strong growth” in its first quarter from the September 1, 2010 to the end of November.
Increased sales of nutritional ingredients in both the infant formula and non-infant formula markets plus the acquisition of health and wellness company Amerifit helped Martek Biosciences achieve a 30 per cent increase in 2010 revenues to reach $450m.
Naturex’s has indicated that the first six months of 2010 have brought strong revenue-growth as it set about integrating the ingredients division recently acquired from Natraceutical, but all its business arms contributed to the fine results.
Food firm Kerry delivers like-for-like trading profit of €134 million at its ingredients and flavours unit for the first half of 2008, thanks in part to 'prudent price actions' that have brought good cost recovery to the group.
Collaboration with customers, cautious pricing, a simplified
structure and innovation all helped Kerry Ingredients achieve
profit increases despite soaring raw material costs.
Martek Biosciences' revenues for Q2 2007 were up nine percent over
the same period in 2006, but operating profits saw a slight dip as
contract manufacturing margins were down and ARA costs rose.
Cognis' nutrition and health sales took a small dip in organic
terms Q1 2007 compared with an exceptionally strong quarter last
year, especially in functional food ingredients.
Forbes Medi-Tech has reported an increase in sales of its Reducol
branded sterols in Q2 2006 by 32 per cent compared to last year,
but losses deepen with dearer development, marketing and sales
costs.
Annual sales at Cyanotech dropped by three percent, as a 27 percent
hike in fourth quarter sales was not enough to offset issues that
beset the Hawaiian microalgae producer in the second and third
quarters.
Cyanotech slipped into the red in 2Q 2006 as a result of
fluctuating spirulina sales and ongoing issues with the Japanese
aquaculture market; meanwhile astaxanthin picked up some of the
slack.
Energy costs and restructuring have hit operating profits at French
plant extracts producer Naturex, causing a 10.5 per cent drop to
€2.2 million for the first half of the year.
Joint health continues to be a major growth area for Weider
Nutrition International, which yesterday reported a 9.8 percent
increase in sales of Q1 2006 driven by joint care brands.
Leiner Health Care buffered the impact of negative publicity about
vitamin E in fiscal 2005 by shifting its focus to joint care
products, writes Jess Halliday.
The stockpiles of Martek products being held by the firm's
customers caused a slowdown in revenue growth for the second
quarter but it claims that extra capacity coming on stream this
year will see a new surge in demand, reports...
Rising raw material costs lead to decline of $0.58m in Galaxy's
gross margin for 3Q 2005, leading to price hikes and expense cuts
throughout the remainder of the fiscal year.
Cyanotech Corporation has reported net income of $326,000 ($0.02
per diluted share) for 3Q 2005, an almost three-fold increase on
$109,000 ($0.01 per dilute share) in 3Q 2004.
Martek Biosciences last week announced its year-end results, noting
increased revenues and "robust growth" due primarily to higher
sales of nutritional products to the company's infant formula
licensees.
UK-based BioProgress, the manufacturer of 'dissolve in the mouth'
films, has bought two soluble film casting lines allowing it to
boost its production capacity to meet growing demand for the novel
delivery format.
